clinical trial · NCT07046923
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company·phase1·recruiting·n = 240
Carcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaEndometrial NeoplasmsNeoplasm MetastasisTriple Negative Breast CancerLY4175408PembrolizumabCarboplatinCisplatin
brief summary
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.
started
Jul 28, 2025
primary completion
Jul 1, 2030
completion
Jul 1, 2030
last updated
Jun 2, 2026
official title
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol